The present invention relates to compounds of general. formula I, wherein the group R1 is defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.本發明係關於通式I之化合物:其中基團R1係如申請專利範圍第1項中所定義,其具有有價值之藥理學性質,特定而言結合至GPR40受體並調節其活性。該等化合物適於治療及預防可受此受體影響之疾病,例如代謝疾病,特定而言2型糖尿病。
